To embed, copy and paste the code into your website or blog:
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Cadence Pharmaceuticals, Inc. et al. v. Fresenius Kabi USA, LLC
3:13-cv-00139; filed January 17, 2013 in the Southern District of California
• Plaintiffs: Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendant: Fresenius Kabi USA, LLC
Infringement of U.S. Patent Nos. 6,028,222 ("Stable Liquid Paracetamol Compositions, and Method for Preparing the Same," issued February 22, 2000) and 6,992,218 ("Method for Obtaining Aqueous Formulations of Oxidation-Sensitive Active Principles," issued January 31, 2006), both licensed to Cadence, following a Paragraph IV certification as part of Fresenius' filing of an ANDA to manufacture a generic version of Cadence's Ofirmev® (acetaminophen injection, used for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fevers). View the complaint here.
Bioprojet SCR v. Kappos
1:13-cv-00055; filed January 14, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,222,294 ("Combinations of an Anti Emetic Agent and an Enkephalinase Inhibitor," issued July 17, 2012). View the complaint here.
Wyeth LLC et al. v. Kappos
1:13-cv-00049; filed January 10, 2013 in the Eastern District of Virginia
• Plaintiffs: Wyeth LLC; Janssen Alzheimer Immunotherapy
• Defendant: Hon. David J. Kappos
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,227,403 ("A-β Immunogenic Peptide Carrier Conjugates and Methods of Producing Same," issued July 24, 2012). View the complaint here.
Topics: Biotechnology, Infringement, Patent Term Adjustment, Patents, Pharmacies
Published In: Civil Procedure Updates, Intellectual Property Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© McDonnell Boehnen Hulbert & Berghoff LLP
Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…
…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.
Create your news brief now - it's free and easy »
At McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB"), we provide creative, pragmatic business...
View Profile »
Back to Top